Twist Bioscience (TWST) Liabilities and Shareholders Equity (2018 - 2026)
Twist Bioscience has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $676.2 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 13.53% to $676.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Mar 2026, up 5.83% year-over-year, with the annual reading at $641.9 million for FY2025, 4.48% up from the prior year.
- Liabilities and Shareholders Equity was $676.2 million for Q1 2026 at Twist Bioscience, up from $638.1 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.0 billion in Q1 2022 and troughed at $595.6 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $702.8 million (2024), against an average of $753.3 million.
- Year-over-year, Liabilities and Shareholders Equity surged 50.84% in 2022 and then dropped 21.25% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $910.0 million in 2022, then fell by 19.47% to $732.8 million in 2023, then fell by 16.95% to $608.6 million in 2024, then rose by 4.85% to $638.1 million in 2025, then grew by 5.98% to $676.2 million in 2026.
- Per Business Quant, the three most recent readings for TWST's Liabilities and Shareholders Equity are $676.2 million (Q1 2026), $638.1 million (Q4 2025), and $641.9 million (Q3 2025).